

CytomX Therapeutics, Inc. Logo

CytomX Therapeutics to Present at Upcoming Healthcare Conferences

August 28, 2019 at 8:00 AM EDT

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its ProbodTM therapeutic technology platform, announced today that Sean McCarthy, D.Phil., president, chief executive officer and chairman, will participate at the following healthcare conferences in September.

Citi 14th Annual Biotech Conference

Panel Discussion: *New Targets in Cancer Immunotherapy and the Tumor Microenvironment*

Date: Wednesday, September 4, 2019
Time: 9:30 a.m. ET
Location: Boston, Massachusetts

H. C. Wainwright 21st Annual Global Investment Conference

Date: Tuesday, September 10, 2019
Time: 10:50 a.m. ET
Location: New York, New York

Live audio webcast of the panel discussion and corporate presentation will be available through the "Investors & News" section of CytomX's website. An archived replay will be available for 60 days following the event.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its ProbodTM therapeutic technology platform. Probod therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while minimizing activity in healthy tissues. CytomX and its partners have four programs in the clinic. The Company's clinical stage pipeline includes cancer immunotherapies against clinically validated targets, including a PD-L1-targeting Probod therapeutic wholly owned by CytomX (CX-072) and a CTLA-4-targeting Probod therapeutic partnered with Bristol Myers Squibb (BMS-986249). The CytomX clinical stage pipeline also includes first-in-class Probod drug conjugates against highly attractive targets, including a CD166-targeting Probod drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probod drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Probod is a trademark of CytomX Therapeutics.

Contact:

Investors and Media:

Christopher Keenan
VP, Investor Relations and Corporate Communications
ckeenan@cytomx.com
650-383-0823



Source: CytomX Therapeutics Inc.